Brokerages forecast that Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) will report earnings of ($0.72) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Zynerba Pharmaceuticals’ earnings. Zynerba Pharmaceuticals reported earnings of ($0.60) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 20%. The company is expected to report its next earnings results on Monday, March 11th.
On average, analysts expect that Zynerba Pharmaceuticals will report full year earnings of ($3.13) per share for the current year, with EPS estimates ranging from ($3.18) to ($3.06). For the next year, analysts expect that the firm will report earnings of ($2.61) per share, with EPS estimates ranging from ($2.68) to ($2.57). Zacks’ EPS calculations are an average based on a survey of analysts that cover Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Thursday, November 8th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.23.
ZYNE has been the subject of several recent analyst reports. Canaccord Genuity set a $18.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 13th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 13th. ValuEngine cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 20th. Cantor Fitzgerald set a $20.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.93.
ZYNE stock opened at $5.95 on Friday. The company has a market cap of $102.22 million, a P/E ratio of -2.40 and a beta of 4.49. Zynerba Pharmaceuticals has a fifty-two week low of $5.03 and a fifty-two week high of $15.14.
In other news, Director John P. Butler purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The shares were bought at an average price of $6.43 per share, with a total value of $32,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $32,150. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.67% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in Zynerba Pharmaceuticals by 385.6% during the first quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock worth $106,000 after buying an additional 9,701 shares during the period. Thompson Siegel & Walmsley LLC acquired a new position in Zynerba Pharmaceuticals during the third quarter worth approximately $157,000. Raymond James & Associates acquired a new position in Zynerba Pharmaceuticals during the second quarter worth approximately $164,000. Zeke Capital Advisors LLC acquired a new position in Zynerba Pharmaceuticals during the third quarter worth approximately $193,000. Finally, Engineers Gate Manager LP acquired a new position in Zynerba Pharmaceuticals during the second quarter worth approximately $231,000. 14.08% of the stock is currently owned by institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.